FDA Brief

Warning letters Food

FDA warning letter to

Hearthy Foods, Inc.

High riskIssued Feb 10Posted May 5Human Foods Program

FDA cited Hearthy Foods after an inspection for CGMP violations in RTE whey protein and dietary supplements, including allergen and pest issues.

What happened

FDA inspected the Los Angeles facility from March 19, 2025, through April 14, 2025, and reviewed product labels collected during the inspection. It found RTE Whey Protein Isolate made under insanitary conditions with inadequate pathogen and allergen controls, plus dietary supplement CGMP failures including missing specifications, records, quality control, and pest control. It also observed apparent rodent droppings in storage areas and misbranding on whey protein and supplement labels.

What FDA found

  1. FDA said the company did not analyze hazards for RTE Whey Protein Isolate, including environmental pathogens, milk allergen, and Salmonella, so required preventive controls were missing.

    21 CFR 117.130(a)(1), 117.130(c)(1)(ii)
  2. FDA found insanitary conditions, including food debris on equipment and surfaces, no sanitizer at stations, poor glove hygiene, and apparent rodent droppings in storage areas.

    21 CFR 117.35(a), 117.35(e), 117.10(b), 111.15(d)(2)
  3. The company lacked finished-product and component specifications for its Collagen products and had no written quality control procedures.

    21 CFR 111.70(e), 111.70(b)(1)-(3), 111.103
  4. The company did not prepare required master manufacturing records and batch production records for its dietary supplement products.

    21 CFR 111.205(a), 111.210, 111.255(a), 111.260
  5. The Whey Protein Isolate label did not declare milk or sunflower lecithin and did not include the protein percent Daily Value required with protein claims.

    21 U.S.C. 343(w), 343(i)(2), 343(q); 21 CFR 101.9(c)(7)
  6. The Collagen and Collagen+ supplement labels did not state that the products are dietary supplements.

    21 U.S.C. 343(s)(2)(B); 21 CFR 101.3(g)

What FDA wants

FDA tells the company to investigate the causes, correct the violations, prevent recurrence, and provide supporting documentation. The provided text does not state a response deadline.

Who should pay attention

  • brands that buy RTE whey protein or supplements from this contract manufacturer
  • supplement brands using shared dry-ingredient storage or packaging
  • food safety teams managing allergen labeling and pest control at contract manufacturers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk